Post by Jack Shuang Hou

💉 LumaCina - Bridgewest Perth Pharma #Appoints Gary Bird as #CEO to Accelerate Global Sterile Injectables Growth Leadership transitions often signal a company’s next strategic chapter. LumaCina - Bridgewest Perth Pharma has appointed Gary Bird as Chief Executive Officer, positioning the company to accelerate global expansion in sterile injectable pharmaceuticals while Mark Crotty continues as Executive Chair, leading long-term strategy and platform development. 1️⃣ Leadership Built for Global Expansion With more than 30 years of pharmaceutical leadership experience, Gary Bird, Chief Executive Officer of LumaCina - Bridgewest Perth Pharma, brings deep expertise in commercial strategy, market expansion and partnership-driven growth. His previous leadership roles at Orion Pharma, Medreich Limited, @Meda, Johnson & Johnson, Sanofi-Aventis, and Pharmacia provide strong experience across pharmaceuticals, contract manufacturing and specialty medicines. 2️⃣ Scaling a Sterile Injectables Platform LumaCina - Bridgewest Perth Pharma manufactures sterile injectable medicines in Perth, Australia, supplying hospitals across Australia, New Zealand, Asia and Northern Europe. The company is expanding through new product development, licensing opportunities, strategic partnerships and acquisitions, with the ambition of becoming a stronger global supplier of essential injectable medicines. 3️⃣ Strong Governance + Commercial Execution The leadership structure combines strategic continuity with commercial execution. While Gary Bird focuses on operational growth, Mark Crotty, Executive Chair of LumaCina - Bridgewest Perth Pharma, will continue guiding long-term strategy and platform expansion. Dr. Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group, also highlighted that this leadership combination provides the continuity and industry expertise needed for the company’s next stage of global growth. 👥 Leadership Perspective Mark Crotty, Executive Chair of LumaCina - Bridgewest Perth Pharma, emphasized that Gary Bird’s proven ability to build trusted commercial partnerships and deliver sustainable growth makes him the ideal leader to strengthen the company’s position as a global supplier of sterile injectable medicines. Gary Bird, Chief Executive Officer of LumaCina - Bridgewest Perth Pharma, noted that healthcare systems increasingly depend on reliable partners capable of consistently supplying high-quality essential medicines, and he sees significant opportunities to expand LumaCina’s global pharmaceutical platform. 🧩 My takeaway The sterile injectables market is becoming increasingly strategic as healthcare systems prioritize supply chain resilience, manufacturing quality and reliable global partners. #LumaCina #BridgewestGroup #SterileInjectables #Pharmaceuticals #Leadership #Healthcare https://lnkd.in/e8kx_M3n